Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference

Harrow, Inc. (Nasdaq: HROW), a prominent provider of ophthalmic disease management solutions in North America, has announced its participation in the upcoming Leerink Partner’s 2026 Global Healthcare Conference, scheduled for March 10, 2026, at 8:40 AM ET in Miami, Florida. This event presents an excellent opportunity for Harrow's management to showcase the company's innovative approaches and advancements in the treatment of various ophthalmic conditions, as they will discuss their comprehensive portfolio that addresses multiple ocular issues, including dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and more.

The conference presentation will be available for live streaming on Harrow's official website, and a replay will be accessible for approximately 90 days after the event. This aligns with Harrow's commitment to transparency and engagement with investors and stakeholders in the healthcare sector.

Harrow has built its reputation on the premise of providing safe, effective, accessible, and affordable medications aimed at enhancing patient compliance and improving clinical outcomes. The company’s efforts are geared toward making significant advancements in the management of eye diseases, ensuring that patients have access to essential treatments that can significantly impact their quality of life.

For those interested in learning more about Harrow's initiatives and offerings, additional information can be found on their website, and stakeholders are encouraged to connect with the company via LinkedIn. As Harrow prepares for this pivotal conference, industry observers and investors will be keen to see how the company positions itself within the evolving landscape of ophthalmic care.

For media inquiries, Mike Biega, Vice President of Investor Relations and Communications, is available.

Harrow (Nasdaq: HROW), a prominent key player in the ophthalmic disease management sector, is poised for increased attention as it prepares for its presentation at the Leerink Partner’s 2026 Global Healthcare Conference in Miami. Scheduled for March 10, 2026, this event will provide an invaluable platform for Harrow to showcase its innovations and strategic direction, particularly in a sector that remains increasingly vital due to the rising prevalence of ocular diseases.

Investors should closely observe Harrow's presentation as it is expected to highlight not only current product offerings targeting various ophthalmic conditions but also future growth strategies. With an expanding portfolio that includes treatments for dry eye disease, age-related macular degeneration, glaucoma, and more, the company is well-positioned to capitalize on the growing demand for innovative eye care solutions.

Moreover, the decision to webcast this presentation demonstrates Harrow's commitment to transparency and investor engagement, as it allows broader audience reach and facilitates real-time feedback. Market participants will want to pay attention to any new clinical data or pipeline advancements that may be shared during the event, which can significantly impact stock movements post-conference.

The ophthalmic market is characterized by its rapid growth and innovation, with increasing focus on patient compliance and outcomes. As Harrow operates at the intersection of healthcare efficiency and patient-centric care, investors might find potential upside as the company aims to enhance its footprint in a market rife with opportunities.

In conclusion, ahead of the conference, investors should consider monitoring Harrow closely for insights into potential growth trajectories and shifts in strategic priorities that can reveal actionable investment opportunities. As the conference approaches, keeping an eye on related trends and market responses will also be essential in crafting an informed investment strategy.